Skip to search formSkip to main contentSkip to account menu

Campath

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

alemtuzumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Tacrolimus monotherapy following alemtuzumab induction in combined kidney-pancreas transplantation: results of a prospective randomized trial.
BACKGROUND We investigated the safety and efficacy of Campath induction and tacrolimus (TAC) maintenance therapy compared to ATG… 
2010
2010
A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas
The clinical course of peripheral T-cell lymphoma (PTCL) is usually aggressive and the prognosis unfavorable. Therefore, there is… 
Review
2009
Review
2009
Improved Progression-Free Survival (PFS) of Alemtuzumab (Campath®, MabCampath®) Plus Fludarabine (Fludara®) Versus Fludarabine Alone as Second-Line Treatment of Patients with B-Cell Chronic…
Abstract 537 Introduction: Single-arm pilot and Phase II trial data suggested that the combination of fludarabine and alemtuzumab… 
Review
2009
Review
2009
Pharmaceutical and cellular strategies in prophylaxis and treatment of graft-versus-host disease.
Acute and chronic GVHD after allogeneic hematopoetic stem cell transplantation are still associated with significant morbidity… 
2006
2006
Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells.
Review
2004
Review
2004
Treatment of refractory autoimmune diseases with ablative immunotherapy.
2004
2004
Combination Chemoimmunotherapy Using Alemtuzumab, Fludarabine, Cyclophosphamide, and Doxorubicin (Campath-FCD) Is an Effective First-Line Regimen in Peripheral T-Cell Lymphomas.
Peripheral (mature) T-cell lymphomas (PTCL) are represented by distinct lymphoma entities, many of which with a rather… 
2004
2004
Immune recovery after low-dose Campath therapy in a group of pretreated patients affected by B-cell chronic lymphocytic leukemia
Immune recovery after low-dose Campath therapy in a group of pretreated patients affected by B-cell chronic lymphocytic leukemia 
2003
2003
Reduced-intensity rituximab-BEAM-CAMPATH allogeneic haematopoietic stem cell transplantation for follicular lymphoma is feasible and induces durable molecular remissions
Summary:The indolent non-Hodgkin's lymphomas are theoretically curable through allogeneic haematopoietic stem cell… 
1997
1997
In vitro T cell depletion using Campath 1M for mismatched BMT for severe combined immunodeficiency (SCID)
Bone marrow transplantation is the only curative treatment for children with severe combined immunodeficiency (SCID). In the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)